Key clinical point: Atopic eczema was associated with a heightened risk of lymphoma, especially non-Hodgkin lymphoma.
Major finding: Adjusted hazard ratios for non-Hodgkin lymphoma in the English cohort were 1.06 (99% confidence interval, 0.90-1.25) for mild atopic eczema, 1.24 (99% CI, 1.04-1.48) for moderate eczema, and 2.08 (99% CI, 1.42-3.04) for severe eczema.
Study details: Two large matched cohort studies conducted from 1998 to 2016 in England and Denmark.
Disclosures: Partial support was provided by the Wellcome Trust, the Royal Society, the Dagmar Marshalls Fund, and the Aase and Ejnar Danielsens Fund. Dr. Mansfield disclosed support from a Wellcome Trust grant. Her coinvestigators disclosed ties to TARGET-DERM, Pfizer, and GlaxoSmithKline, and from the Wellcome Trust, Medical Research Council, the National Institute for Health Research, the British Heart Foundation, Diabetes UK, and IMI Horizon 2020 funding BIOMAP.
Mansfield KE et al. JAMA Dermatol. 2020 Jun 24. doi: 10.1001/jamadermatol.2020.1948.